Expert Rev Pharmacoecon Outcomes Res. 2022 Dec 21. doi: 10.1080/14737167.2023.2161048. Online ahead of print.
NO ABSTRACT
PMID:36541133 | DOI:10.1080/14737167.2023.2161048
Categories
Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor targeted agents matter?
